COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
Anne M. Hause(Centers for Disease Control and Prevention), David K. Shay(National Center for Emerging and Zoonotic Infectious Diseases), Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Paige Marquez(Centers for Disease Control and Prevention), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Deborah Thompson(New Mexico Department of Health), Tanya R. Myers(Centers for Disease Control and Prevention), Charles Licata(Department of Human Services), Winston E. Abara(Centers for Disease Control and Prevention), John R. Su(National Center for Emerging and Zoonotic Infectious Diseases), Julianne Gee, James Baggs
Cited by 167
Related Papers
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
|JAMA|2022|670
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
|PubMed|2014|537
Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021
|Preventing Chronic Disease|2021|370
Enhancing disease surveillance with novel data streams: challenges and opportunities
|EPJ Data Science|2015|239